Here's Why "Trend" Investors Would Love Betting on China Resources Power Holdings Co. (CRPJY) – Yahoo Finance

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.
The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.
Investors looking to make a profit from stocks that are currently on the move may find our "Recent Price Strength" screen pretty useful. This predefined screen comes handy in spotting stocks that are on an uptrend backed by strength in their fundamentals, and trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
China Resources Power Holdings Co. (CRPJY) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors.
A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. CRPJY is quite a good fit in this regard, gaining 110.6% over this period.
However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 4.4% over the past four weeks ensures that the trend is still in place for the stock of this company.
Moreover, CRPJY is currently trading at 95.2% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises — the key factors that impact a stock's near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance.
So, the price trend in CRPJY may not reverse anytime soon.
In addition to CRPJY, there are several other stocks that currently pass through our "Recent Price Strength" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
China Resources Power Holdings Co. (CRPJY) : Free Stock Analysis Report
To read this article on click here.
In order for Bitcoin to reach $60k, a new catalyst must emerge, and a quick one might lead to record highs
More Americans now use fintech than they do video-streaming subscriptions and social media, according to a new report by fintech startup Plaid.
'The Big Short' guy remains bearish. But he's long on this trio of stocks.
It's been a harrowing quarter for Novavax (NASDAQ: NVAX) investors. The stock is down by more than 13% over the last three months, and even with approval for its coronavirus vaccine candidate seemingly in sight, it's reasonable to wonder whether the company's stock is worth purchasing. Based on its upcoming catalysts, I think Novavax's losing streak will end before the close of 2021, and that rumors of its demise are exaggerated.
DatChat (NASDAQ: DATS), which develops a privacy-oriented messaging app, went public at $4.15 per share (and one warrant for an additional share) on Aug. 12. Let's see why DatChat has attracted so much attention. DatChat's Messenger and Private Social Network enable users to modify or delete the messages they've sent, hide encrypted messages, and set messages to be automatically deleted after a fixed time frame or a set number of views.
Industry researchers dished out yet another warning that Micron's pricing power is under pressure.
American multinational technology company International Business Machines Corporation (IBM) announced that its Board of Directors has approved the long-pending separation of Kyndryl, IBM’s managed infrastructure service business. After the separation, IBM will focus on its core hybrid cloud and artificial intelligence (AI) solutions business. Following the news, shares sank 1.4%, closing at $140.47 on October 12. As per the terms, IBM shareholders will receive 80.1% of Kyndryl’s common stock on
In this article, we discuss the 10 best stocks under $10 according to billionaire Daniel Och’s OZ Management. You can skip our detailed analysis of the billionaire’s hedge fund history, and go directly to read the 5 Best Stocks Under $10 According to Billionaire Daniel Och’s OZ Management. Daniel Och is an American billionaire, investor, […]
Sarepta Therapeutics stock is falling after the biotech company said it would sell more stock and provided an update on product revenue. Sarepta said that it would post third-quarter sales of $166.9 million. Sarepta stock had 6.6% in premarket trading after gaining 4.1% on Tuesday.
Decrypt Editor-in-Chief Dan Roberts breaks down what crypto investors need to know about Shiba Inu. 
AT&T Inc (NYSE: T) is trading lower Monday after Barclays analyst Kannan Venkateshwar maintained the stock with an Equal-Weight rating and lowered the price target from $34 to $30. The Barclays analyst cited challenging technicals as a result of the equity performance at Discovery Inc (NASDAQ: DISCA), which AT&T will be merging its media business with. AT&T was among the top three trending stocks on Stocktwits at publication time. AT&T is set to announce its third-quarter financial results befor
If the latest short-seller attack on Ginkgo Bioworks has you nervous about synthetic biology, consider the industry leader.
Shares of Amkor Technology (NASDAQ: AMKR), a semiconductor packaging and test services company, were falling today after the company's stock received a downgrade from Credit Suisse analyst Randy Abrams. Abrams downgraded Amkor's stock to a neutral rating, down from outperform, and put a price target on the stock of $27, which was down from $28.50. Of course, investors don't like to see a stock get downgraded or for its target price to be lowered, so it's no surprise that Amkor's stock took a hit today.
As Q4 gets into full swing, we can take a moment to look back over our shoulders at where we’ve come from. The sustained upward trend of the markets is obvious from this view, and the recent downturn in the market appears as a bump against some otherwise solid gains. Even so, there are reasons for concern right now. The COVID pandemic hasn’t gone away – and it doesn’t look like it will go away either. The September jobs numbers were weak, and unemployment only fell because too many people left t
The biotech stock, which has had a volatile year, is a favorite of retail investors because of its potential for a short squeeze.
Consider these five high-quality tech stocks enjoying "big picture" growth trends as potential building blocks for your portfolio. The company is growing its Cash App, which enables users to store and send money. Now with 40 million monthly users, Cash App has a long growth runway ahead of it.
Few bank stocks have as much hope baked into them as Citigroup (Ticker: C), and one analyst’s patience for a turnaround is wearing thin. Citigroup had no immediate comment. Citigroup shares currently trade at 0.8 times book value, making it the only big bank stock to trade below book, a metric commonly used to value banks.
Yahoo Finance’s Jared Blikre reports on the day's trending tickers.
Some of the reasons behind the vaccine stock's sell-off appear to be much ado about nothing. But not all of them.
The short squeeze is usually something inflicted by one hedge fund on another. This is really the first time we have seen such trading instigated by a band of retail traders.